BiotechTube

Rilzabrutinib + Placebo + Glucocorticoid

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin G4 Related Disease

Conditions

Immunoglobulin G4 Related Disease

Trial Timeline

Sep 26, 2025 → Dec 25, 2030

NCT ID
NCT07190196

About Rilzabrutinib + Placebo + Glucocorticoid

Rilzabrutinib + Placebo + Glucocorticoid is a phase 3 stage product being developed by Sanofi for Immunoglobulin G4 Related Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07190196. Target conditions include Immunoglobulin G4 Related Disease.

What happened to similar drugs?

0 of 3 similar drugs in Immunoglobulin G4 Related Disease were approved

Approved (0) Terminated (0) Active (3)
🔄iptacopanNovartisPhase 3
🔄Felzartamab + PlaceboBiogenPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07190196Phase 3Recruiting

Competing Products

11 competing products in Immunoglobulin G4 Related Disease

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
39
zigakibartNovartisPhase 2
42
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
InebilizumabAmgenPhase 2
42
rilzabrutinib + GlucocorticoidsSanofiPhase 2
35
FelzartamabBiogenPhase 2
32
Felzartamab + PlaceboBiogenPhase 3
44
SparsentanTravere TherapeuticsPhase 2
29
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38